

CURRICULUM VITAE
(Revised December 2013)

NAME: **COULL, Bruce MacLean, M.D.**

PRESENT POSITION:

Sept 2008 - Present	Vice Dean, College of Medicine Deputy Dean, Clinical Affairs, University of AZ College of Medicine Chief Medical Officer, The University of Arizona Physicians
Aug 2005 – Sept 2009	William M. Feinberg, MD Endowed Chair in Stroke Research University of Arizona-College of Medicine
	Joint Appointment as: Professor, Departments of Medicine & Neurology Adjunct Senior Research Investigator Translational Genomics Research Institute

PROFESSIONAL ADDRESS:

University of Arizona
College of Medicine
Department of Neurology, Rm 2212
1501 N. Campbell
Tucson, Arizona 85724-5017
Phone: 520\626-9286
FAX #: 520\626-6252

PRACTICE ADDRESS:

University Physicians Healthcare, Inc.
Neurology – 2800 E. Ajo Way
P. O. Box 245005
Tucson, AZ 85713

EDUCATION:

1958-62	Mt. Lebanon High School, Pennsylvania
1962-66	University of Pittsburgh; B.S. Degree, Chemical Engineering
1968	University of Pittsburgh; M.S. Degree, Chemical Engineering
1968-72	University of Pittsburgh; School of Medicine, M.D. Degree

LICENSES AND CERTIFICATION:

State of Arizona	23787
State of California	G26428 (inactive)
State of Oregon	11612 (inactive)
American Board of Psychiatry and Neurology, 1979	
ABPN in Vascular Neurology, May, 2005-2015	

PREVIOUS POSITIONS:

1995-2008	Professor & Head, Department of Neurology, University of Arizona
1985-1995	Chief of Service, Department of Neurology Veterans Administration Medical Center, Portland, OR
1991-1995	Professor of Neurology

1982-1995	Oregon Health Sciences University (OHSU), Portland, OR Director, Comprehensive Stroke Center of Oregon Oregon Health Sciences University, Portland, OR
1979-1995	Director, Stroke Clinic Oregon Health Sciences University, Portland, OR
1984-1991	Associate Professor of Neurology Oregon Health Sciences University, Portland, OR
1978-84	Assistant Professor of Neurology Oregon Health Sciences University, Portland, OR
1976-78	NIH Fellow in Developmental Neurology Stanford University, Stanford, California
1973-76	Stanford University Hospital, Stanford, California (Neurology Residency)
1972-73	Presbyterian University Hospital, Pittsburgh, PA (Internship)

AWARDS AND HONORS:

1976-78	NIH Fellow in Developmental Neurology Stanford University, Stanford, California
1987	Allen J. Hill Award for Teaching Excellence in the Clinical Sciences
1991	The Markham Hill Society Lecture "Stroke: Causes, Treatment, Cures"
2005	Distinguished Alumni Award for Department of Chemical & Petroleum Engineering, University of Pittsburgh
2005	William M. Feinberg, MD Endowed Chair in Stroke Research
2007	Fellow, American Heart Association
2003 – 2007	Chair of NIH- National Institute of Neurological Disorders and Stroke (NINDS) Neurological Sciences and Disorders K (NSD-K) Committee
2007-2008	Best Doctors in America

TEACHING/TRAINING ACTIVITIES:

Postdoctoral fellows in Stroke

Robert Hart, M.D. with Professor Frank Yatsu
 Vincent Miller, M.D. with Professor Frank Yatsu
 Arun B. Shah, M.D.
 Yongji Tan, M.D.
 Dennis Briley, M.D.
 Michael Wynn, D.O.
 L. Roderick Anderson, M.D.
 David A. Brenner, M.D.
 Jeremy R. Payne, M.D.
 Douglas Franz, M.D.

MEMBERSHIPS IN PROFESSIONAL SOCIETIES:

Current	Diplomate, National Board of Medical Examiners
1976	Junior Associate Member, American Academy of Neurology
1978	American Epilepsy Society
1978	American Association for the Advancement of Science
1979	Active Member, American Academy of Neurology
1980	Oregon Neuropsychiatric Society (Vice President, Fall 1982)
1985	International Society of Biorheology
1991	American Neurological Association

EDITORIAL AND REVIEWING ACTIVITIES:

NIH

1995-1999	NINDS NSP-A Neuroscience Review Committee Member
1987-1989	NINDS Monitoring Committee for the International Cooperative Study of Intracranial Aneurysm and Subarachnoid Hemorrhage: Randomized Trial of Nicardipine HCl
2004-Pres.	Data Safety Monitoring Board for THINRS
Present	Data Safety Monitoring Board for LEAPS
Present	Data Safety Monitoring Board for GRASP
Present	Data Safety Monitoring Board for 2CARES
Present	Data Safety Monitoring Board for ICARE

Ad hoc editorial consultant for the following journals:

Neurology
Clinical Hemorheology
Circulation
Biorheology
Annals of Neurology
Journal of the Neurological Sciences
Journal of Cerebral Blood Flow and Metabolism

Editorial Board: Current

Journal of Stroke and Cerebrovascular Diseases (Demos Publications)
Stroke: American Heart Association
Journal of Rehabilitation and Health (Plenum Publishing)

Ad hoc Grant Reviewer:

NINDS, Stroke Center Application Grant, 1982
Allegheny-Singer Foundation, Pittsburgh, Pennsylvania, 1988
Contract Grants Reviewer, NINDS, "rt-PA in Acute Brain Infarction", 1989
Henry Ford Hospital Research Foundation Applications, Detroit, MI (Numerous)
NINDS, Stroke Program Project Grant Application, Univ. Southern California, 1992
American Heart Association grant reviewer, 2001 to present

CURRENT ADMINISTRATIVE EXPERIENCE:

UMC	July, 1995 – Present	Medical Executive Committee
	Feb, 1999 – June 1999	Chair, Information Services (Electronic Medical Record)
	July, 1995 – Present	Department Heads Council

Jan, 2009 – Present Chief Medical Director, Primary Stroke Center

UPH Sept 2008 – Present Leadership Advisory Committee
Sept 2009 – Present County Steering Committee
Sept 2008 – Present Financial Advisory Subcommittee
Sept 2008 – Present Faculty Practice Plan
Sept 2008 – Present Practice Base Executive Committee
Sept 2008 – Present Compliance Committee
Sept 2008 – Present Credentialing Committee
Sept 2008 – Present Policies & Procedures Committee
July, 1995 – Present UPH Executive Committee
July, 1995 – Present Operations Committee
July, 1996 – 2006 Joint Claims Committee
July, 1995 – 1997 UPI Board of Directors
Apr, 1996 – 1998 Co-Chair, Committee on Member Compensation

COM July, 1995 – Present Chief Rounds, Dept of Neurology (Teaching)
July, 1998 – Present Student Appeals Committee
July, 1999 – 2000 Chair, Search Committee for Director of Arizona Liver Institute
July, 1999 – Present Executive Board of Sarver Heart Center
April 2007 – Present Phoenix/COM – Banner Affiliation Steering Committee
Jan, 2009 – Present Promotion & Tenure Committee, Neurology

NATIONAL/PROFESSIONAL

2003 – 2007 Chair of NIH- National Institute of Neurological Disorders and Stroke (NINDS) Neurological Sciences and Disorders K (NSD-K) Committee
2000 – 2003 Association of University Professors of Neurology (AUPN), Second Vice President
1999 – 2001 National Academy of Science - Member, IOM Committee on a Vision for Space Medicine Beyond Earth Orbit
1999 – 2003 American Heart Assn/American Academy of Neurology, Chair, Anticoagulants & Antithrombotic Agents in Acute Stroke Panel
1999 – Present Western States Stroke Consortium, Officer

PROFESSIONAL SOCIETY ACTIVITIES:

American Board of Psychiatry and Neurology, Inc., Examiner (four sites)
American Academy of Neurology (AAN)

Committee Assignments:

1994-1995 Section on Stroke and Vascular Neurology: Member Executive Committee

Course Director or Faculty:

Faculty: Breakfast Seminar No 110 - "Antiphospholipid Antibodies" 46th Annual Meeting AAN, May 1, 1994, Washington, D.C.
Faculty: Breakfast Seminar No 413 - "Evaluation and Management of Stroke in Young Adults" 46th Annual Meeting AAN, May 7, 1994, Washington, D.C.
Faculty: Breakfast Seminar - "Antiphospholipid Antibodies" 45th Annual Meeting AAN, May 1, 1993, New York, NY.

- Faculty: Full-day Courses - "Cerebrovascular Disorders" 44th Annual Meeting AAN, May 3, 1992, San Diego, Ca.
- Faculty: Breakfast Seminar - "Antiphospholipid Antibodies" 44th Annual Meeting AAN, May 9, 1992, San Diego, Ca.
- Director: Breakfast Seminar - "Antiphospholipid Antibodies in Neurologic Disease" 43rd Annual Meeting AAN, April 27, 1991, Boston, Mass.
- Faculty: Breakfast Seminar - "Antiphospholipid Antibodies in Neurologic Disease" 42nd Annual Meeting AAN, May 6, 1990, Miami Beach, Fla.
- Faculty: Breakfast Seminar - "Antiphospholipid Antibodies in Neurologic Disease" 41st Annual Meeting AAN - April 13, 1989, Chicago, Ill.
- Faculty: Scientific Basis of Neurology 43rd Annual Meeting AAN, April 22, 1991, Boston, Mass.

PUBLICATIONS:

Chapters, Books, and Miscellaneous Reviews:

1. Cutler RWP and **Coull BM**. Amino acid transport in the brain. In: **Taurine and Neurological Disorders** (Barbeau A and Huxstable RJ, eds). Raven Press, New York, NY, pp 95-107, 1978.
2. Yatsu FM and **Coull BM**. Acute medical therapy of ischemic strokes and the role of prostaglandins. In: **Advances in Stroke Therapy** (Rose RC, ed). Raven Press, New York, NY, pp 95-107, 1982.
3. **Coull BM**. Cerebrovascular disease. In: **Geriatric Medicine: Principles and Practice**, (Cassel C and Walsh J, eds). Springer-Verlag, New York, NY, pp 25-35, 1984.
4. **Coull BM**. Neurologic aspects of dementia. In: **Geriatric Medicine: Principles and Practice**, (Cassel C and Walsh J, eds). Springer-Verlag, New York, NY, pp 36-49, 1984.
5. **Coull BM**, Shah AB, Beamer NB and Miller VT. Enhanced in vivo platelet activation and subtypes of ischemic stroke. In: **Cerebrovascular Diseases**, (Plum F and Pulsinelli W, eds). Raven Press, New York, NY, pp 229-235, 1985.
6. Miller VT, **Coull BM**, Yatsu FM, Shah AB and Beamer NB. Prostacyclin therapy for acute stroke. In: **Cerebrovascular Diseases**, (Plum F and Pulsinelli W, eds). Raven Press, New York, NY, pp 235-239, 1985.
7. Binder LM, Howieson D and **Coull BM**. Stroke: Causes, consequences and treatment. In: **Rehabilitation Psychology Desk Reference**, (Caplan B, ed). Aspen Publishing Company, Rockville, MD, pp 65-100, 1987.
8. Yatsu FM and **Coull BM**. Barbiturates therapy of ischemic strokes. In: **Medical Therapy of Acute Stroke**, (Fisher M, ed). Marcel Dekker, Inc., New York, NY, pp 109-114, 1989.
9. **Coull BM**, Mela-Riker L and Tan Y. Calcium channel blockers in stroke. In: **Medical Therapy of Acute Stroke**, (Fisher M, ed). Marcel Dekker, Inc., New York, NY, pp. 143-163, 1989.

10. **Coull BM**, Nordt F, Beamer NB and Seaman GVF. Hemorheological abnormalities as physicochemical risk factors for cerebral infarction. In: **Cerebral Ischemia and Hemorheology**, (Hartmann A and Kuschinsky W, eds). Springer-Verlag, Berlin-Heidelberg, pp. 520-527, 1987.
11. Makler MT, Piper RC and **Coull BM**. Erythrocyte membrane changes associated with ligands which bind to the glycoporphins. In: Red Blood Cells as Carriers for Drugs; Potential Therapeutic Applications: **Advances in Biotechnology**, Volume 67. Pergamon Press, pp 251-260, 1987.
12. Seaman GVF, Beamer NB, **Coull BM**, deGarmo P, Knox RJ, and Nordt FJ. Relationship between bulk flow properties of blood and carotid artery changes in cerebrovascular disease. In: **International Symposium on Biofluid Mechanics, Blood Flow in Large Arteries: Applications to Atherogenesis and Clinical Medicine**, (Leipsh D, ed). Proceeding Production, The Brown Agency, Rancho Mirage, CA, 1988.
13. Beamer NB, **Coull BM**, Illingworth DR, Hagemenas FC, Nordt FJ, Knox RJ, deGarmo P, and Seaman GVF. Effect of lipid lowering therapy on blood viscosity in familial hyperlipidemia. : **16th Princeton Conference on Cerebral Vascular Diseases**, (Ginsberg M and Dietrich WD, eds). Raven Press, New York, NY, pp. 281-287, 1989.
14. **Coull BM**. Stroke in the young patient - coagulation disturbances. In: *Stroke: Clinical Updates*, Volume 1. National Stroke Association, Englewood, CO, pp. 9-12, 1990.
15. **Coull BM**, Levine SR, Brey RC. The role of Antiphospholipid Antibodies in Stroke. Cerebral Ischemia: Treatment and Prevention (HJM Barnett, ed) Neurologic Clinics 10:125-143,1992.
16. **Coull BM**, Briley DP. "Rehabilitation and Outcome of Ischemic Stroke" in: **Cerebrovascular Occlusive Disease and Brain Ischemia**. (Awad, AA, ed.) Neurosurgical Topics The American Association of Neurological Surgeons pp. 265-280,1992.
17. **Coull BM**, Goodnight SH. Antiphospholipid Antibodies and Coagulation Disorders in Ischemic Stroke. In **STROKE: Pathophysiology, Diagnosis, and Management**, *second edition*. (Henry J.M. Barnett, J.P. Mohr, Bennett M. Stein, Frank M. Yatsu, editors). Churchill Livingstone Inc. New York, NY, pp 859-873,1992.
18. **Coull BM**, Goodnight SH. Hematological abnormalities in stroke. In **Handbook of Cerebrovascular Diseases**, (Harold P. Adams, Jr., Editor). Marcel Dekker, Inc. New York, NY, pp 191-220,1993.
19. Clark WM, **Coull BM**, Beamer NB. Need for treatment of elevated plasma fibrinogen in cerebrovascular disease. Heart Disease and Stroke 2:503-506,1993.
20. **Coull BM**, Beamer NB, Clark WM, Howard G. Acute Phase Response in Atherothrombotic Stroke In: **Cerebrovascular Diseases, Nineteenth Princeton Stroke Conference** (Moskowitz MA and Caplan LR, eds). Butterworth-Heinemann, Boston MA, pp. 111-122, 1995.
21. Wynn ML, **Coull BM**. Evaluation of ischemic stroke and recurrent ischemic attack. **Laboratory Medicine** 26:519-523, 1995.

22. **Coull, BM.** The many windows of therapeutic opportunities in stroke. **Current Opinion in Neurology** 9:43-45, 1996
23. Brey RL, **Coull BM.** Cerebral venous thrombosis. Role of activated protein C resistance and factor V gene mutation (editorial; comment). *Stroke* 27(10):1719-20, 1996.
24. Oddone E, Booss J, Brass LM, **Coull B,** Goldstein L, Gorelick P, Horner R, Matchar D, Provenzale J, Kaplan L. Acute stroke management in the VA: A toolbox to assist patient care. *Federal Practitioner*, (in press).
25. Levine SR, **Coull BM.** Potassium depletion as a risk factor for stroke. Will a banana a day keep your stroke away? (editorial) *Neurology*, 59:302-303, 2002.
26. **Coull BM,** Brey R. Coagulation abnormalities in stroke. In: Stroke – Pathophysiology, Diagnosis, and Management, 4th Ed, (Mohr JP, Choi DW, Grotta JC, Weir B, Wolf PA, Eds). Churchill Livingstone: New York, NY 707-724, 2004.
27. **Coull BM,** Woodbury-Harris KM. (Eds.) Clinical Trials in the Neurosciences. 2009. S. Karger Publishers: Unionville, CT

Articles

1. Retzlaff DG, **Coull BM,** Coull J. A microchemical study of gas-phase kinetics for three irreversible reactions. *Journal of Physical Chemistry* 74:2455-59, 1970.
2. Chorbajian T, **Coull BM,** Coull J. An in numero study of glucose-insulin interaction. *Bulletin of Mathematics and Biophysics* 33:451-62, 1971.
3. **Coull BM,** Pedley TA. Intermittent photic stimulation: Clinical usefulness of non-convulsive responses. *Electroencephalography and Clinical Neurophysiology* 44:353-363, 1978.
4. **Coull BM,** Cutler RWP. Light-evoked release of endogenous glycine into the perfused vitreous of the intact rat eye. *Investigative Ophthalmology and Visual Science* 17:682-684, 1978
5. **Coull BM,** Owens DK and Cutler RWP. The release of endogenous amino acids into the vitreous of the intact eye of the albino rat: Effect of light, potassium and ouabain. *Brain Research* 210:301-309, 1981.
6. Rosenberg NL, **Coull BM.** Myelopathy after scorpion sting. *Archives of Neurology* 39:127, 1982.
7. Porter JM, Rivers SP, **Coull BM,** Baur GM. Thoracic outlet syndrome: A conservative approach. *Vascular Diagnosis and Therapy* 3:35-39, 1982.
8. Woodward WR, **Coull BM.** Studies of effect of kainic acid lesions in the dorsal lateral geniculate nucleus of rat. *Journal of Comparative Neurology* 211:93-103, 1982.
9. Hart RG, **Coull BM** and Hart. Early recurrent embolism associated with nonvalvular atrial fibrillation: A retrospective study. *Stroke* 14:688-693, 1983.

10. Hakim AM, Furlan AJ, Hart RG, **Coull BM** and the Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: A randomized trial. *Stroke* 14:668-676, 1983.
11. The American-Canadian Cooperative Study Group. Progress Report: Persantine aspirin trial in cerebral ischemia. *Stroke* 14:99-103, 1983.
12. Woodward WR and **Coull BM**. Localization and organization of geniculocortical and corticofugal fiber tracts within the subcortical white matter. *Neuroscience* 12:1089-1099, 1984.
13. Miller VT, **Coull BM**, Yatsu FM, Shah AB, Beamer NB. Prostacyclin infusion in acute cerebral infarction. *Neurology* 34:1431-1436, 1984.
14. Hakim AM, Furlan AJ, Hart RG, **Coull BM**, and the Cerebral Embolism Study Group. Immediate anticoagulation of embolic stroke: Brain hemorrhage and management options. *Stroke* 15:779-789, 1984.
15. Hart RG, Miller VT, **Coull BM**, Brill V. Cerebral infarction associated with lupus anticoagulants - preliminary report. *Stroke* 15:114-118, 1984.
16. The American-Canadian Cooperative Study Group. Persantine aspirin trial in cerebral ischemia, Part II: Endpoint results. *Stroke* 16:406-415, 1985.
17. Hakim AM, Furlan AJ, Hart RG, **Coull BM**, and the Cerebral Embolism Study Group. Cardioembolic stroke, early anticoagulation, and brain hemorrhage. *Archives of Internal Medicine* 147:630-640, 1987.
18. Shah AB, Beamer NB, **Coull BM**. Enhanced in vivo platelet activation in subtypes of ischemic strokes. *Stroke* 16:643-647, 1985.
19. Gumerlock MK, **Coull BM**, Howieson J, Buchan C, Neuwelt EA. Late stenosis of a superficial temporal-middle cerebral artery bypass: Angiographic and histological findings. *Neurosurgery* 16:650-657, 1985.
20. Yatsu FM, Becker C, McLeroy KR, **Coull BM**, Feibel J, Howard G, Toole JF, Walker MD. Community Hospital-Based Stroke Programs: North Carolina, Oregon, and New York. I. Goals, objectives and methodology. *Stroke* 17:276-284, 1986.
21. Becker C, Howard G, McLeroy KR, Yatsu FM, Toole JF, **Coull BM**, Feibel J, Walker MD. Community Hospital-Based Stroke Programs: North Carolina, Oregon, and New York. II. Description of study population. *Stroke* 17:285-293, 1986.
22. Howard G, Walker MD, Becker C, **Coull BM**, Feibel J, McLeroy K, Toole JF, Yatsu F. Community Hospital-Based Stroke Programs: North Carolina, Oregon, and New York. III. Factors influencing survival after stroke: Proportional hazards analysis of 4219 patients. *Stroke* 17:294-299, 1986.
23. Linz DH, de Garmo PL, Morton WE, Wiens AN, **Coull BM** and Maricle RA. Organic solvent-induced encephalopathy in industrial painters. *Journal of Occupational Medicine* 28:119-125, 1986.

24. **Coull BM**, Beamer NB, Seaman GVF. Physicochemical risk factors in stroke. Fourth European Conference on Clinical Hemorheology. Part II. Round Table: Cerebral Ischemia and Clinical Haemorheology. *Clinical Hemorheology* 6:17-33, 1986.
25. Hsu CY, Faught RE Jr, Furlan AJ, **Coull BM**, Huang DC, Hogan EL, Linet OI, Yatsu FM. Intravenous prostacyclin in acute non-hemorrhagic stroke: A placebo controlled double blind trial. The Prostacyclin Study Group. *Stroke* 18:352-358, 1987.
26. **Coull BM**, Bourdette DN, Briley DP, Goodnight SH and Hart R. Multiple cerebral infarctions and dementia associated with anticardiolipin antibodies. *Stroke* 18:1107-1112, 1987.
27. Woodward WR, **Coull BM**. Effects of kainic acid lesions in lateral geniculate nucleus: Activity-dependence of retrograde axonal transport of fluorescent dyes. *Brain Research* 454:106-115, 1988.
28. Tan Y, **Coull BM**, Knox RJ, Beamer NB, Seaman GVF, Mela-Riker L and Nordt FJ. Red blood cell fragility in acute cerebral ischemia: Effects of calcium ions and flunarizine. *Clinical Hemorheology* 9:273-279, 1989.
29. Briley DP, **Coull BM**, Goodnight SH. Neurological disease associated with anticardiolipin antibodies. *Annals of Neurology* 25:221-227, 1989.
30. Mao C, **Coull BM**, Golper LC, Rau MT. Anterior operculum syndrome. *Neurology* 39:1169-1172, 1989.
31. Woodward WR, Meshul CK, **Coull BM**. Ultrastructural and functional evidence for the survival of corticogeniculate neurons in kainic acid lesioned lateral geniculate nucleus. *Brain Research* 494:42-54, 1989.
32. Malinow MR, Kang SS, Taylor LM, Wong PWK, **Coull BM**, Inahara T, Mukerjee D, Sexton G and Upson B. Prevalence of hyperhomocyst(e)anemia in patients with peripheral arterial occlusive disease. *Circulation*, 79:1180-1188, 1989.
33. Woodward WR, Chiaia N, Tyler TJ, Leong L and **Coull BM**. Organization of cortical afferent and efferent pathways in the white matter of the rat visual system. *Neuroscience* 36:393-401, 1990.
34. **Coull BM** and Goodnight SH. Antiphospholipid antibodies, prethrombotic states, and stroke. *Current Concepts of Cerebrovascular Disease and Stroke* 25:13-18, 1990.
35. Nordt FJ, Seaman GVFS, **Coull BM**, and Beamer NB. Hemorheological profiles of diabetic stroke patients and diabetic individuals at high risk for stroke. *Clinical Hemorheology*
36. Nordt FJ, Jack W, and **Coull BM**. Influence of Naftidrofuryl, a serotonergic antagonist on erythrocyte aggregation. *J. Cardiovasc. Pharm* 16 (Suppl 3):529-532, 1990.
37. **Coull BM**, Malinow MR, Beamer N, Sexton G, Nordt F, and de Garmo P. Elevated plasma homocyst(e)ine: a possible independent risk factor for stroke. *Stroke* 21:572-576, 1990.
38. **Coull BM**, Brockschmidt JK, Howard G, Becker C, Yatsu FM, Toole JF, McLeroy KR, and

- Feibel J. Stroke diagnosis and its relationship to demographics, risk factors and clinical status after stroke. *Stroke* 21:867-873, 1990.
39. Howard G, Brockschmidt JK, **Coull BM**, Becker C, Feibel J, Walker MD, McLeroy KR, Toole JF, and Yatsu FM. Stroke Diagnosis: Factors influencing the diagnostic evaluation of patients following acute stroke. *Clinical Epidemiology* 44:293-301, 1991.
 40. **Coull BM**, Beamer N, de Garmo P, Sexton G, Nordt F, Knox R, Seaman GVF. Chronic blood hyperviscosity in subjects with acute stroke, transient ischemic attack, and risk for stroke. *Stroke* 22:162-168, 1991.
 41. Clark WM, **Coull BM**, Corliss L, Beamer N, Austin T, de Garmo P, Briley DP. Role of leucocyte adhesion in clinical stroke. *Journal of Cerebrovascular Disease* 2:80-84,1992.
 42. **Coull BM**, Clark WM. Abnormalities of hemostasis in ischemic stroke. *Med Clin North Am* 77:77-94,1993.
 43. Clark WM, Walsh CR, Briley DP, **Coull BM**. Neutrophil adhesion in central nervous system ischemia in rabbits. *Brain Behavior and Immunity* 7:63-69,1993.
 44. Clark WM, **Coull BM**, Briley DP, Mainolfi E, Rothlein R. Circulating intercellular adhesion molecule-1 levels and neutrophil adhesion in stroke. *Journal of Neuroimmunology* 44:123-126,1993.
 45. Beamer NB, **Coull BM**, Sexton G, de Garmo P, Knox R, Seaman G. Fibrinogen and the albumin/globulin ratio in recurrent stroke. *Stroke* 24:1133-1139,1993.
 46. Goodnight SH, **Coull BM**, McAnulty JH, Taylor LM. Recommendations for the use of antiplatelet therapy in cardiac, cerebral and peripheral vascular disease. Part I *Western J Med* 158:385-392,1993.
 47. Goodnight SH, **Coull BM**, McAnulty JH, Taylor LM. Recommendations for the use of antiplatelet therapy in cardiac, cerebral and peripheral vascular disease. Part II *Western J Med* 158:506-514,1993.
 48. Olson JC, Konkol RJ, Gill JC, Dobyn WB, **Coull BM**. Childhood stroke and lupus anticoagulant. *Pediatric Neurology* 10:54-57,1993.
 49. Clark W, Hotan T, Lauten J, **Coull BM**. Therapeutic efficacy of tirilazad in experimental multiple cerebral emboli. *Critical Care Med.* 22,1161-1166,1994.
 50. Clark WM, Calcagno FA, Gabler WL, Smith JR, **Coull BM**. Reduction of central nervous system reperfusion injury in rabbits using doxycycline treatment. *Stroke* 25:1411-1416,1994.
 51. Briley DP, Giraud GD, Beamer NB, Spear EM, Grauer SE, Edwards JM, Clark WM, Sexton GJ, **Coull BM**. Spontaneous echo contrast and hemorheologic abnormalities in cerebral vascular disease. *Stroke* 25:1564-1569,1994.
 52. Barnwell SL, Clark WM, Nguyen TT, O'Neil OR, Wynn ML, **Coull BM**. Safety and efficacy of delayed intra-arterial urokinase therapy with mechanical clot disruption for thromboembolic stroke. *AJNR* 15:1817-1822,1994.

53. Beamer NB, **Coull BM**, Clark WM, Hazel JS, Silberger JR. Interleukin 6 and interleukin 1 receptor antagonist in acute stroke. *Annals of Neurology* 37: 800-805, 1995
54. Grotta J, Clark W, **Coull B**, Pettigrew C, Mackay B, Goldstein L, Meissner I, LaRue L. Safety and tolerability of the glutamate antagonist CGS19755 (Selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. *Stroke* 26:602-605, 1995.
55. Clark W, Lauten J, Beamer N, **Coull B**. Cytokine and superoxide production in clinical stroke. *J Stroke and Cerebrovascular Disease*, 5:166-171, 1995.
56. Clark W, Lauten J, Lessov N, Woodward W, **Coull B**. Time course of ICAM-1 expression and leukocyte subset infiltration. *Molecular and Chem NeuroPath* 26:213-230, 1995.
57. Clark W, Barnwell S, Nesbitt G, O'Neill O, Wynn M, **Coull B**. Safety and efficacy of percutaneous transluminal angioplasty for intracranial atherosclerotic stenosis. *Stroke* 26:1200-1204, 1995.
58. Clark W, Lauten J, Lessov N, Woodward W, **Coull B**. The influence of antiadhesion therapies on leukocyte subset accumulation in central nervous system ischemia in rats. *Journal of Molecular Neuroscience* 6:43-50,1995.
59. Clark W, Hazel J, **Coull B**. Lazaroids: central nervous system pharmacology and current research. *Drugs* 50:971-983,1995.
60. Grotta J, Clark W, **Coull BM**, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. *Stroke*, 26:602-5, 1995.
61. Press RD, Liu XY, Beamer N, **Coull BM**. Ischemic Stroke in the Elderly: Role of the Common Factor V Mutation Causing Resistance to Activated Protein C. *Stroke* 27:44-48, 1996.
62. Clark W, **Coull B**, Hendin B, Kelly R, Rosing H, Zachariah S, Reivich M, Walsche T, Singer S. Randomized trial of cervine, a kappa receptor selective opioid antagonist, in acute ischemic stroke. *J Stroke CerebroVasc Dis* 6:35-39, 1996.
63. Beamer N, Giraud G, Clark W, Wynn M, **Coull B**. Diabetes, hypertension and erythrocyte aggregation in acute stroke. *J Stroke CerebroVasc Dis* 7:144-149, 1997.
64. Mohr JP, Albers GW, Amarenco P, Babikian VL, Biller J, Brey RL, **Coull BM**, Easton JD, Gomez CR, Helgason CM, Case CS, Pullicino PM, Turpie AG. American Heart Association Prevention Conference, IV. Prevention and Rehabilitation of Stroke. Etiology of Stroke. (Meeting Report) *Stroke* 28:1501-6, 1997.
65. Clark WM, Beamer NB, Wynn M, **Coull BM**. The initial acute phase response predicts long-term stroke recovery. *J Stroke CerebroVasc Dis* 7:128-131, 1998.
66. Beamer NB, **Coull BM**, Clark WM, Briley DP, Wynn M, Sexton G. Persistent inflammatory response in stroke survivors. *Neurology* 50:1722-1728, 1998.

67. Kowdley KV, **Coull BM**, Orwoll ES. Cognitive impairment and intracranial calcification in chronic hypoparathyroidism. *American Journal of the Medical Sciences*. 317:273-7, 1999.
68. Press RD, Beamer NB, Evans A, **Coull BM**, DeLoughrey TG. A common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase (MTHFR) in ischemic stroke. *Diagnos Molec Pathol* 8:54-58, 1999.
69. Beamer NB, **Coull BM**, Clark WM, Wynn M. Microalbuminuria in ischemic stroke. *Arch Neurol* 56:699-702, 1999.
70. Secomb TW, Hsu R, Beamer NB, **Coull BM**. "Theoretical simulation of oxygen transport to brain by networks of microvessels: Effects of oxygen supply and demand on tissue hypoxia." *Microcirculation* 7:237-247, 2000.
71. Ritter LS, Orozco JA, **Coull BM**, McDonagh PF. Leukocyte accumulation and hemodynamic changes in the cerebral microcirculation during early reperfusion after stroke. *Stroke* 31:1153-1161, 2000.
72. Fridriksson J, Holland AL, **Coull B**, Plante E, Trouard T, Plante E. Aphasia severity: Association with cerebral perfusion and diffusion. *Aphasiology*, 16:859-871, 2002.
73. Ruehl, ML., Orozco, JA., Stoker, MB., McDonagh, PF., **Coull, B.**, Ritter, LS. Protective effects of inhibiting both blood and vascular selectins after stroke and reperfusion. *Neurological Research*, 2002; 24: 226 – 32..
74. **Coull BM**, Williams LS, Goldstein LB et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). *Stroke* 2002; 33:1934-1942.
75. Funk JL, Migliati E, Chen G, Wei H, **Coull B**, et al. Parathyroid hormone-related protein induction in focal stroke: A neuroprotective vascular peptide. *Am J Physiol* 2002.
76. Austin H, Chimowitz MI, Hill H, **Coull B**, et al. Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. *Stroke* 2002; 33:2762-2769.
77. Levine SR., **Coull B**. Potassium depletion as a risk factor for stroke: will a banana a day keep your stroke away? *Neurology* 2002; 59: 302 – 3.
78. **Coull, Bruce M**. Statin therapy after acute ischemic stroke in the Heart Protection Study: Is the role in recurrent stroke prevention now defined? *Stroke* 2004; 35:2233-2234.
79. Payne JR, **Coull BM**. Antithrombotic therapy for stroke in young adults. *Journal of Thrombosis & Thrombolysis* 2005; 20:127-132.
80. Barbara Radziszewska, Robert G. Hart, Philip A. Wolf, Ralph B. D'Agostino, Sr., Jeffrey A. Cutler. **Bruce M. Coull** (contributing author) Clinical research in primary stroke prevention: Needs, opportunities, and challenges. *Neuroepidemiology* 2005; 25:91-104.
81. Coull, Bruce M. Inflammation and Stroke: Introduction. *Stroke* 2007;38 [part2]:631.

82. Bruno A, Kent T, **Coull BM** et al. Treatment of hyperglycemia in ischemic stroke (THIS): A randomized pilot trial. *Stroke* 2008;39:384-389.
83. Camargo ECS, Oliveira-Filho J, Oliveira LMB, Vieira de Melo RM, Malbouisson I, Ribeiro ISN, Santos CCS, Fonseca DM, Lacerda AM, Viana LC, Reis FJFB, Koroshetz WJ, **Coull BM**, Furie KL. White blood cell genomic response in Chagas disease: Pilot study using RNA expression profiling. *Neurology* 2008 (in press)
84. Ritter, L., Funk J., Schenkel, L., Tipton, A., Downey, K., Wilson, J., **Coull, B.** McDonagh, P. Inflammatory and hemodynamic changes in the cerebral microcirculation of aged rats after global cerebral ischemia and reperfusion. *Microcirculation*; 2008; 15: 297-310.
85. Brenner D, Zweifler R, Gomez C, **Coull B**, Kissela B, Howard G, Levine D, Howard V. Inadequate Awareness and Control of Vascular Risk Factors in Stroke Patients: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *Journal of Stroke and Cerebrovascular Disease* 2009 (in press).
86. **Coull, B.**, Woodbury-Harris, KM. Frontiers of neurology and neuroscience. Clinical trials in the neurosciences. Introduction. *Frontiers of Neurology & Neuroscience* 2009; 25: 1 – 3.
88. Coull BM. Statins: Not just for the young or the faint of heart. *Neurology* 2009; 72(8): 684-5.
89. Coleman, WP., Woodbury-Harris, KM., **Coull, B.** Phase I/II – design and analysis. *Frontiers of Neurology & Neuroscience* 2009; 25: 52 – 4.
90. Franz, D., **Coull, B.** Clinical research training opportunities and elements. *Frontiers of Neurology & Neuroscience* 2009; 25:203 - 5
91. Brenner DA, Zweifler RM, Gomez CR, Kissela BM, Levine D, Howard G, **Coull BM**, Howard VJ. Awareness, treatment, and control of vascular risk factors among stroke survivors. *J Stroke & Cerebrovascular Diseases*, Jul – Aug 2010;19(4):311-320. [Journal Article. Research Support, N.I.H., Extramural. Research Support, U.S. Gov't., Non-P.H.S.]
92. Hsu, FC., Sides, EG., Mychaleckyj, JC., Worrall, BB., Elias, GA., Liu Y., Chen, WM., **Coull B.**, Toole JF., Rich, SS., Furie, KL., Sale, MM. Transcobalamin 2 variant associated with poststroke homocysteine modifies recurrent stroke risk. *Neurology*, October 2011. 77:1543-50.
93. Taylor-Piliae, R., Latt, LD., Hepworth, JT., **Coull, B.** Predictors of gait velocity among community-dwelling stroke survivors. *Gait & Posture*, March 2012; 35:395-9
94. Lin, TP., Thompson, R., **Coull, B.** A 28-year-old i.v. drug user with bilateral basal ganglia and brainstem lesions. *Neurology* February 2013; 80:e-73 – 6. [Case reports. Journal Article]
95. **Coull B**, Taylor-Piliae R. Community-based Yang-style Tai Chi is Safe and Feasible in Chronic Stroke: A Pilot Study; *Clinical Rehabilitation*, March, 2012, Issue 26.3
96. Taylor-Piliae RE, Hepworth, JT, **Coull BM.** Predictors of Depressive Symptoms among Community-Dwelling Stroker Survivors. *Journal of Cardiovascular Nursing* [PMID:

22710739], in press.

97. Taylor-Piliae RE, Boros D, **Coull BM**. Strategies to Improve Recruitment and Retention of Older Stroke Survivors to a Randomized Clinical Exercise Trial. *Journal of Stroke and Cerebrovascular Disease* [PMID: 23643477], in press.

Abstracts and Letters

1. Intermittent photic stimulation: Clinical usefulness of non-convulsive response. American EEG Society. Miami, Florida, June 1977.
2. Light evoked release of glycine into the vitreous of the intact rat eye. Transactions of the American Society of Neurochemistry Abstracts 9:100, 1978.
3. Phipps T, **Coull BM**, Duvall ER and Howieson J. Correlation of CT findings with magnitude of stroke deficit. North Pacific Society of Neurology and Psychiatry. Bend, Oregon. March 26, 1980.
4. Cawthor ML, **Coull BM** and Smith WB. Significance of increased serum alkaline phosphatase in epileptics. North Pacific Society of Neurology and Psychiatry. Bend, Oregon. March 27, 1980.
5. Yatsu FM, **Coull BM**, Osterud HT and Kennedy JH. Impact on stroke care in a mixed urban/rural population: use of "stroke teams." Crisis in the Public Sector: Challenge to the Public Health, Program and Abstracts: 140, 1980.
6. Woodward WR and **Coull BM**. Kainic acid neurotoxicity in the rat lateral geniculate nucleus. Society of Neuroscience Abstracts 6:838, 1980.
7. **Coull BM** and Woodward WR. Evidence against acetylcholine as a neurotransmitter of rat geniculocortical neurons. American Society of Neurochemistry Abstracts 12:244, 1981.
8. Connor WR, Rapp J, Lin D and **Coull BM**. The source of cholesterol ester in human atherosclerosis: Plasma vs. Local synthesis. American Federation of Clinical Research. San Francisco, CA. April 24-26, 1981.
9. Yatsu FM, **Coull BM**, Toole JF, McElroy K, Feibel JH, Springer CA and Walker MD. Regional stroke survey: Demography and outcome. *Stroke* 13:124, 1982.
10. Miller VT, **Coull BM**, Seaman GVF and Jackson L. Anti-aggregate effects of ibuprofen: A potential alternative treatment of TIAs in aspirin-intolerant patients. *Neurology* 32:A-197, 1982.
11. Howard G, Toole JF, Becker C, McElroy K, Feibel J, Springer C, Yatsu FM, **Coull BM** and Walker MD. Survivorship of strokes: Regional stroke survey. *Neurology* 32:A-187, 1982.
12. Hart RG, **Coull BM**, Miller VT and Yatsu FM. Evaluation of cerebral infarction in young adults. *Neurology* 32:A-198, 1982.

13. Woodward WR, **Coull BM** and Kaplan M. Segregation of corticofugal and geniculocortical *Science* 22:244, 1982.
14. **Coull BM**, Woodward WR and Weleber RG. Effect of kainic acid lesions in the lateral geniculate nucleus on the corticofugal pathways of the rat visual system. *Investigative Ophthalmology and Visual Science* 22:244, 1982.
15. Hart RG, Miller VT and **Coull BM**. Rebound hypercoagulability. (Letter) *Stroke* 13:527, 1982.
16. Hart RG, Miller VT and **Coull BM**. Medical management of subarachnoid hemorrhage. (Letter) *Stroke* 13:722-723, 1982.
17. Hart RG, **Coull BM** and Miller VT. (Letter) *Neurology*, 1982.
18. Woodward WR and **Coull BM**. Is retrograde axonal transport of fluorescent dyes dependent on impulse activity in neurons? *Society of Neuroscience Abstracts* 8:789, 1982.
19. Hart RG and **Coull BM**. Practical considerations in antifibrinolytic therapy. *Stroke* 13:5, 1982.
20. Shah AB, **Coull BM**, Howieson J, Ono H, Nutt JG, Blank NK and Carter J. Does the natural history of transient ischemic attacks (TIA) justify surgery? (Letter) *Stroke* 14:827-828, 1983
21. Hart RG and **Coull BM**: Hypercoagulability following Coumadin withdrawal (Letter) *Stroke* 14:133, 1983.
22. Toole JF, Feibel J, Yatsu FM, Becker C and **Coull BM**. Comprehensive Stroke Center Data Base in North Carolina, Oregon and Monroe County, New York. *Annals of Neurology* 14:133, 1983.
23. Shah AB, **Coull BM** and Beamer NB. In vivo platelet activation and strokes in young adults with migraine. *Neurology* 33 [Suppl 2]:206, 1983.
24. Woodward WR and **Coull BM**. Organization of geniculocortical and corticofugal fiber tracts within the subcortical white matter. *Investigative Ophthalmology and Visual Science* 24:64, 1983.
25. **Coull BM** and Woodward WR. Dependence of retrograde fluorescent dye transport on impulse activity in corticogeniculate neurons. *Investigative Ophthalmology and Visual Science* 24:226, 1983.
26. Woodward WR and **Coull BM**. Course and structural organization of geniculocortical and corticofugal pathways in white matter of the rat visual system. *Society Neuroscience Abs.* 9:35, 1983.
27. Shah AB, **Coull BM** and Beamer NB. Differences in platelet activation in subtypes of ischemic stroke. *Stroke* 15:184, 1984.
28. Shah AB, Blank NK and **Coull BM**. Controversy of heparin therapy in stroke in evolution" (SIE): Need for a well designed study. *Neurology* 34, Supplement 1:284, 1984.
29. Shah AB, **Coull BM**, Beamer NB, Miller VT and Howieson J. Platelet activation in stroke:

Evidence supporting a causal role of platelets in subtypes of ischemic stroke. *Neurology* 34 [Suppl 1]:203, 1984.

30. Shah AB, **Coull BM** and Beamer NB. Failure of aspirin to prevent in vivo platelet activation in acute stroke. *Annals of Neurology* 16:154, 1984.
31. Lezak MD, **Coull BM** and Wiens AN. Neuropsychological deficit patterns associated with exposure to airborne toxic substances. 13th Annual Meeting of the International Neuropsychological Society, San Diego, California, February 1985.
32. **Coull BM**, Beamer NB, Seaman GVF and Nordt FJ. Contributions of hemorheological factors to stroke. *Clinical Hemorheology* 5:666, 1985.
33. Seaman GVF and **Coull BM**. Physiochemical risk factors in stroke. *Clinical Hemorheology* 5:711, 1985.
34. **Coull BM**, Beamer NB and Seaman GVF. The contribution of hemorheologic factors to cardioembolic stroke. *Journal of Neurology* 232:197, 1985.
35. **Coull B**, Bourdette D, Goodnight Jr S, Gill T, Hart R. Multiple cerebral infarctions associated with antibodies to cardiolipins. *Neurology* 36[Suppl 1]:252, 1986.
36. Woodward WR, Gumerlock MK, Walker CM, Leong L, Gill TH and **Coull BM**. Morphometric changes in cortical neurons following ischemia. *Society of Neuroscience Abstracts* 12:64, 1986.
37. Meshul CK, Woodward WR, Walker CM and **Coull BM**. Survival of axon terminals in a kainic acid lesion site: A retrograde transport and electron microscopic study. *Society of Neuroscience Abstracts* 12:96, 1986.
38. **Coull BM**, Beamer NB, Seaman GVF and Illingworth RD. Hemorheological profile in patients with familial hypercholesterolemia: Effect of lipid lowering therapy. Abstracts of the 5th European Conference. *Clinical Hemorheology* 7:468, 1987.
39. Tan Y, **Coull BM**, Nordt FJ, Knox RJ, Beamer NB and Seaman GVF. Red blood cell fragility in cerebral ischemia: Influence of flunarizine. Abstracts of the 5th European Conference. *Clinical Hemorheology* 7:467, 1987.
40. Briley DP, **Coull BM** and Goodnight Jr SH. Neurological disease associated with anticardiolipin antibodies. *Annals of Neurology* 22:136, 1987.
41. deGarmo PL, **Coull BM**, Sexton G, Beamer NB, Knox RJ, Seaman GVF and Nordt FJ. Whole blood viscosity as a measure for degree of risk in stroke. *Neurology* 38:296, 1988.
42. Gumerlock MK, Walker CM, Woodward WRW, **Coull BM**. Kainic acid protection against post-ischemic seizures. *Stroke* 19:142, 1988.
43. **Coull BM**. Solicited Editorial response to "Stroke in an intravenous drug user secondary to lupus anticoagulant" by Taber KA and Anderson B. *Stroke* 19:274-275, 1988 (letter with editorial reply by Coull BM).

44. Knox RJ, Beamer NB, **Coull BM**, Nordt FJ, deGarmo PL and Seaman GVF. Red blood cell sialic acid and blood viscosity in heart valve patients. *Blood* 7(5) Supplement 1:29A, 1988.
45. **Coull BM**, Beamer NB, Knox R, deGarmo P, Nordt FJ and Seaman GVF. Plasma components of elevated whole blood viscosity in acute stroke. *Stroke* 20:136, 1989.
46. **Coull BM**, Malinow MR and Beamer N. Elevated plasma homocysteine in acute stroke: relationship to risk factors. *Neurology* 39 [Suppl]:303, 1989.
47. **Coull BM**, Sexton G, Beamer N, and Nordt F. Physiologic, Pharmacologic, and Epidemiologic Variables which distinguish subjects with acute stroke from those at risk. *Neurology* 40 [Suppl]: 324, 1990.
48. Nordt FJ, **Coull BM**, Beamer NB, deGarmo PL, Stevry A: Controlled study of rheological factors in subjects with acute cerebral infarction, TIA and at-high-risk for stroke. Abstracts: First World Congress of Biomechanics 2:277. La Jolla, CA 1990.
49. **Coull BM**, Beamer NB, deGarmo PL, Sexton GJ, Nordt FJ: Plasma proteins, diabetes mellitus, and recurrent stroke. *Stroke* 22: Jan 1991.
50. Briley DP, **Coull BM**. Antiphospholipid antibodies and vascular dementia. *Neurology* 41 (Suppl 1):296,1991.
51. **Coull BM**, Briley DP, Beamer NB, Clark WM. Stroke recurrence, stroke mechanism, and diabetes mellitus. *Neurology* 42 (Suppl 3):272,1992.
52. Clark WM, **Coull BM**, Briley DP, Walsh CR. Neutrophil adhesion in experimental central nervous system ischemia. *Stroke* 42 (Suppl 3):361,1992.
53. Clark WM, Briley DP, **Coull BM**. Leucocyte adhesion in clinical stroke. *Stroke* 23:152, 1992.
54. Briley DP, Giraud G, Spear G, **Coull BM**, Edwards J, Clark WM. Spontaneous echo contrast, ischemic stroke, and risk of recurrent stroke. *Annals of Neurology* 32:237, 1992.
55. **Coull BM**, de Garmo PL, Beamer NB, Briley DP, Clark Wm. Application of the Framingham Stroke Risk Profile to stroke recurrence: the Oregon Stroke Center Database. *Annals of Neurology* 32:265-266,1992.
56. Spear EM, Briley DP, Grauer SE, Edwards JM, Clark WM, **Coull BM**, Giraud GD. Spontaneous echo contrast, fibrinogen and plasma viscosity in stroke patients. *Circulation*, 1992.
57. **Coull BM**, Beamer NB, Clark WM. Elevated plasma interleukin-6 in acute stroke. *Stroke* 24:183,1993.
58. Briley DP, **Coull BM**, Beamer NB, de Garmo PL, Clark WM. Relationship between carotid stenosis and elevated fibrinogen in stroke. *Stroke* 24:186,1993.
59. Clark WM, Barnwell SL, **Coull BM**. Safety and efficacy of delayed intra-arterial urokinase therapy for thromboembolic stroke. *Stroke* 24:190,1993.

60. Clark WM, Hotan T, Lauten J, **Coull BM**. Tirilazad improves neurologic recovery and reduces neutrophil adhesion in experimental stroke. *Neurology* 43 (Suppl 2):A366,1993.
61. **Coull BM**, Austin T, Beamer N, Clark WM. Relationship between the NIH stroke scale , the Mini-Mental Status Exam, and functional stroke outcome. *Neurology* 43 (Suppl 2):A244, 1993.
62. Clark W, Lauten J, **Coull B**, Cherry N, Woodward W. ICAM-1 and IL-6 changes in the hippocampus following transient forebrain ischemia in the rat. *Soc Neurosci*. (in press).
63. Hazel S, **Coull BM**, Beamer N, Clark WM, McCall AL. Fibrinogen and poor early outcome after ischemic stroke. *Stroke* 25:246, 1994.
64. **Coull BM**, Briley DP, Clark WM, Beamer N, Giraud G. Spontaneous echo contrast (SEC) in ischemic stroke: the role of cardiac and hemorheologic abnormalities. *Stroke* 25:258, 1994.
65. Clark WM, Lauten JD, Woodward WW, **Coull BM**. Delayed ICAM-1 expression and macrophage infiltration on rat forebrain ischemia. *Stroke* 25:266, 1994.
66. Clark WM, Calcagno FA, Smith J, Gabler WL, **Coull BM**. Therapeutic efficacy of doxycycline in experimental CNS reperfusion injury. *Stroke* 25:266, 1994.
67. Clark WM, Barnwell SL, Young LM, **Coull BM**. Safety and efficacy of angioplasty for intracranial atherosclerotic stenosis. *Stroke* 25: 273, 1994.
68. Wynn M, Clark W, Radakovich E, **Coull B**. Risk of cerebrovascular events in cardiac transplant patients. *Neurology* 44(Suppl 2): A128, 1994.
69. Lauten JD, Clark WM, Woodward WR, **Coull BM**. Time course of ICAM- expression and leukocyte subset infiltration in rat forebrain ischemia. *Neurology* 44(Suppl 2): A191, 1994.
70. Clark WM, **Coull BM**, for the CGS 19755 Study Group. Randomized trial of CGS 19755, a glutamate antagonist, in acute ischemic stroke treatment. *Neurology* 44(Suppl 2): A270, 1994.
71. **Coull BM**, Beamer N, Clark W. Elevated fibrinogen and plasma interleukin-6 (IL-6) in acute stroke. *Neurology* 44(Suppl 2): A289, 1994.
72. Clark WM, Calcagno FA, Smith JR, Gabler WL, **Coull BM**. Doxycycline improves neurologic recovery and reduces leukocyte adhesion in experimental central nervous system ischemia. *Neurology* 44(Suppl 2): A341, 1994.
73. Clark W, Barnwell S, O **Coull B**, Successful middle cerebral artery thrombolysis by microcatheter navigation through an occluded internal carotid artery. *Stroke* 26:167, 1995.
74. **Coull BM**, Beamer N, Clark W, Ramsay C, Hazel S. Enhanced erythrocyte aggregation in acute stroke. *Stroke* 26:162, 1995.
75. Clark WM, Lauten J, Lessov N, Woodward W, **Coull B**. Anti-adhesion treatments modify leukocyte subset accumulation in rat forebrain ischemia. *Stroke* 26:169,1995.

76. Clark WM, Lauten J, Hazel K, Lessov N, **Coull B**. Doxycycline improves functional outcome after transient middle cerebral artery occlusion in the rat. *Neurology* 45(suppl 4): A311,1995.
77. Clark WM, **Coull B**, Hendin B, Kelly R, Rosing H, Zachariah S, Winograd M, Reivich M, Walshe T. Randomized trial of cervine, a kappa receptor selective opioid antagonist, in acute ischemic stroke. *Neurology* 45(Suppl 4): A241,1995.
78. Clark WM, Lauten JD, Lessov N, Hazel K, **Coull BM**. Inhibition of leukocyte adhesion in experimental CNS ischemia. *Biorheology* 32: 162-169, 1995.
79. Beamer N, Giraud G, Wynn M, Clark WM, Nygard C, **Coull BM**. Glycosylated hemoglobin and RBC aggregation in stroke. *Biorheology* 32:163-169, 1995.
80. **Coull BM**, Beamer N, Anderson G, Clark WM, Ramsay C, Giraud G, Hazel S. Erythrocyte aggregation in subtypes of ischemic stroke. *Biorheology* 32:163-169, 1995.
81. Giraud GD, Grauer SE, Beamer NB, Clark WM, **Coull BM**. The relationship between spontaneous echo contrast and hemorheologic abnormalities in patients with cerebrovascular disease. *Biorheology* 32: 163-169, 1995.
82. **Coull BM**, Beamer N, McAnulty J, Giraud G, Clark WM. Clinical and Rheological Risk for Thromboembolism in Atrial Fibrillation. *Stroke* 27: 166, 1996.
83. Clark WM, Hazel S, Beamer N, Wynn M, **Coull BM**. The Initial Acute Phase Response Predicts Long Term Stroke Recovery. *Stroke* 27: 186, 1996.
84. **Coull BM**, Beamer N, Clark W, Wynn M. Angiotensin-Converting Enzyme Inhibitors Reduce Risk of Recurrent Stroke, Myocardial Infarction and Vascular Death. *Neurology* 46: 424, 1996.
85. Press RD, Beamer N, **Coull B**. A common mutation in methylenetetrahydrofolate reductase in stroke. *Stroke* 28: 265, 1997.
86. **Coull B**, Beamer N, Clark W, Wynn M. Influence of cerebro- and cardiovascular risk factors on recurrent stroke. *Stroke* 28: 238, 1997.
87. **Coull B**, Beamer N, Clark W, Wynn M. Persistently elevated fibrinogen after atheroembolic stroke. *Neurology* 48(2):A372. 1997.
88. **Coull BM**, Beamer NB, Clark WM, Wynn M. Microalbuminuria and the risk of recurrent stroke. *Stroke* 29: 285,1998.
89. Ritter LS, **Coull BM**, Davis-Forman G, McDonagh PF. Early in reperfusion following stroke, leurocytes rapidly accumulate in the cerebral microcirculation. *Stroke* 29: 329, 1998.
90. Feldman LA, Wynn M, **Coull BM**, McAnulty JH, Giraud GD. The relationship between left atrial spontaneous echocardiographic contrast and cerebral microemboli in patients with atrial fibrillation. *Circulation* 96(8):1-104, 1997.
91. **Coull BM**, Beamer NB. Serum potassium levels in ischemic stroke. *Neurology* 52(2):A105-

A106, 1999.

92. Beamer NB, **Coull BM**. Vitamin use in patients with ischemic stroke. *Neurology* 52(6) Suppl 2:A64, 1999.
93. Leslie S. Ritter, **Bruce M. Coull**, Paul F. McDonagh, "Middle cerebral artery occlusion and reperfusion results in significant leukocyte accumulation in the microcirculation." **The FASEB Journal**, 13(5): 13.29, March 15, 1999.
94. L. Ritter, **B. Coull**, P. McDonagh, and J. McDonagh. Reduced shear rate is associated with significant leukocyte accumulation in the cerebral microcirculation after middle cerebral artery occlusion and reperfusion." **Soc. Neuroscience Abstr**, 25:1033, 1999.
95. Secomb, TW, Hsu R, Beamer NB, **Coull BM**: Effects of blood perfusion and oxygen consumption of brain tissue: Theoretical simulation of oxygen transport by networks of microvessels. *Stroke* 31:341, 2000.
96. L. Ritter, J. Orozco, **B. Coull**, and P. McDonagh. An increase in leukocyte rolling in venules is observed during early leukocyte reperfusion after stroke. **The FASEB Journal**, 14, A13, 2000.
97. Fridriksson J, Holland AL, **Coull BM**, Plante E, Beeson P, Trouard T. Association between cerebral perfusion/diffusion and aphasia severity in stroke. *Stroke* 33:366, 2002.
98. Levine SR, **Coull BM**,. Potassium depletion as a risk factor for stroke: Will a banana a day keep your stroke away? *Neurology* 2002; 59:302-303.
99. Olson SE, Early WK, **Coull BM**. Stroke etiology affects DWI lesion pattern in single territory ischemic strokes. *Neurology* 2003; 60 (Suppl 1): A309.
100. Olson SE, Bamber D, Lyden P, **Coull BM**. Multiple DWI abnormalities are not sensitive or specific for embolic sources in anterior circulation strokes. *Stroke* 2006; 37:287
101. Brenner D, McDonagh P, **Coull B**. Thromboelastography to assess aspirin resistance in acute atroke. European Stroke Conference, May 2006.
102. Brenner D, McDonagh P, **Coull B**. Poor agreement in detecting aspirin resistance in stroke. American Academy of Neurology Meeting, May 2007.
103. Brenner D, Zweifler R, Gomez C, **Coull B**, Kissela B, Howard G, Levine D, Howard V. Inadequate awareness and control of vascular risk factors in stroke patients: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. International Stroke Conference, February 2008.
104. Brenner D, McClure L, Levine D, Zweifler R, Safford M, Rhodes D, Gomez C, **Coull B**, Kissela B, Howard G, Howard V. Behavioral modifiable risk factors in stroke patients: The REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. American Academy of Neurology Conference, May 2009.

SCHOLARLY PRESENTATIONS:

COLLOQUIA:

Sarver Heart Center, University of Arizona (invited); "Stroke Prevention and Treatment," Green Valley, AZ	January 1997
Sarver Heart Center, University of Arizona (invited); "Cardiovascular Update: What's New in Stroke Prevention," Tucson, AZ	May 1997
Small group dinner talk (invited); "New Paradigms in the Treatment of Stroke," Tucson, AZ	June 1999
Small dinner group talk (invited): "Update on Stroke Management." Portland, OR	June 2001
Small dinner group talk (invited): "Antiplatelets in Stroke & TIA." Montgomery, AL	May 2002
Small roundtable talk (Pharmaceutical invite); "Preventing Recurrent Strokes.," Chandler, AZ	May 2002
Peer-to-Peer talk (invited); "The Clinical Significance of Stroke Recurrence and Prevention." Boehringer-Ingelheim sponsored at French Café in Omaha, NE	December 2003
Small group dinner talk (invited); "Brain Attacks; Causes, Treatment, and Cures." Sierra Vista Regional Health Center at Pueblo del Sol Country Club, Sierra Vista, AZ	January 2004
Small group dinner talk (invited); "The Importance of Antiplatelet Therapy in Stroke." At Janos Restaurant, Tucson, AZ	June 2005
Small group dinner talk (invited); "Current and Emerging Treatment Options in Antiplatelet Therapy." Donovan's in La Jolla, CA	June 2005
Peer-to-Peer talk (invited); Pharmaceutical dinner talk at City Grille; "Best Practices in Stroke Care: Managing Risk Factors." Tucson, AZ	September 2005
Small group dinner talk (invited) Sierra Vista Regional Health Center; "New Updates in Treatment of Stroke." Bisbee, AZ	January 2006
Sarver Heart Center Speaker Series 2005-2006 (invited); "Stroke: Prevention & Treatment." Tucson, AZ	February 2006
Distinguished Lecture Series (invited); "Primary and Secondary Stroke Prevention: Pathways of Care." Flagstaff Medical Center, Flagstaff, AZ	May 2006
Peer-to-Peer talk, Sierra Vista Regional Health Center; "Quality Improvement in Recent Stroke: Improving Guideline Adherence and Patient Outcomes."	July 2006
Medical Education Resources presentation (invited). "Strategies for the Application of Novel Therapies for Multiple Sclerosis," New York, NY	March 2007
Carondelet St. Mary's Hospital presentation (invited). "Stroke Update 2007",	

Tucson, AZ

July 2007

Montclair Neurology grand rounds (invited) "Prevention of Secondary Stroke in Stroke & TIA, Birmingham, AL

September 2007

SEMINARS:

American Academy of Neurology Annual Meeting (invited); "Antiphospholipid Antibodies," Boston, MA	April 1997
CME Seminar: "Lipid Lowering Therapy in Cerebrovascular Disease," Tucson, AZ	July 1999
Medicom of Princeton Seminar – New Directions of Stroke Prevention (invited); "Antiplatelet Therapy." Atlanta, GA	March 2001
American Stroke Association (invited); "Antithrombotic Therapy."	April 2002
Stroke Speakers Meeting, Naples FL (Invited); "Non-antithrombotic Therapies for Stroke Prevention.	January 2003
Department of Veterans Affairs (invited); "Acute Management of CVAs," VAMC, Tucson, AZ	March 2003
55 th Annual Meeting of the American Academy of Neurology (invited): Seminar title: An Evidence-Based Approach: Stroke Prevention and Treatment; Lecture title: "Anticoagulation/Antithrombotic Therapy for Acute Ischemic Stroke."	April 2003

SYMPOSIA:

Oregon Health Sciences University (invited); "Stroke Risk Factors – Homocysteine," Portland, OR	April 1998
American Academy of Neurology Annual Meeting (invited); "Unusual Causes of Stroke," Toronto, Canada	April 1999
Oregon Health Sciences University (invited); "Neurology 2000: Evolution from a Diagnostic to a Therapeutic Specialty," Portland, OR	October 2000
4 th World Stroke Congress (satellite symposium on The Role of Statin Therapy in Stroke Prevention– invited); "The Potential Role of Atorvastatin in Stroke Prevention." Melbourne, Australia	November 2000
American Academy of Neurology 54 th Annual Meeting (invited); "Stroke Prevention in 2002," Denver, CO	April 2002
American Academy of Neurology (invited); "Acute Stroke: Principles of Modern Management,"	October 2002
1 st Northeast Regional Symposium: Diagnostic and Treatment of Cerebrovascular Diseases (invited); "Prothrombotic Disorders and Stroke." College of Neurology of Sinaloa, Mexico	March 2003
American Academy of Neurology 55 th Annual Meeting (invited); "An Evidence Based Approach: Stroke Prevention and Treatment," Honolulu, HI	April 2003

Cardiovascular Disease and the Aggressive Lipid Lower Therapy Symposia (invited); "Blood Cholesterol, Lipid Agents and the Risk of Stroke." Tokyo, Japan	May 2003
International Stroke Conference 2005 (invited); "Carotid Disease of Young and Old: Who Does it Affect and How Should It Be Treated?" Hilton Riverside Hotel, New Orleans, LA	February 2005
American Heart Association (invited); "Get With the Guidelines" Tucson, AZ	May 2004
INSPIRE Stroke Care Continuum (invited); "The Latest in Secondary Stroke Prevention." Ritz Carlton Hotel, Phoenix, AZ	June 2004
31 st Annual Barrow Symposium (invited); "Stroke in Young Adults." Barrow Neurological Institute, Phoenix, AZ	March 2005
33 rd Annual Barrow Symposium (Invited). "Neuroprotection and Antiplatelet Therapy", Phoenix, AZ	February 2007
34 th Annual Barrow Sympopsia (Invited) "Medical Management of Chronic Stroke", Phoenix, AZ	March 2007
Neurology Symposium 2007 (invited) "Stroke", Banner Good Samaritan Medical Center, Phoenix, AZ	April 2007
Resident Research Forum 2007 (Keynote Speaker) "Clinical Research Trials, Tucson AZ	June 2007
Symposia on Stroke (Invited) "Stroke Update 2007", Tucson AZ	July 2007
Neurology in the 21 st Century (Invited) "Preventing Stroke, What's New?" Portland, OR	Sept 2007

CONFERENCES:

International Joint Conference on Stroke & Cerebral Circulation (submitted); Anaheim, CA	February 1997
Neurology Grand Rounds – Medical College of Georgia (invited) ; “Hyperhomocysteinemia: Biology of Stroke,” Augusta, GA	April 1997
Neurology Grand Rounds – University of Minnesota (invited); “Preparing for the 21 st Century: Biology of Stroke,” Duluth, MN	April 1997
2 nd Pacific Rim Conference on Hypertension (invited); “Hypertension in Special Populations” and “Stroke in Young People,” Manila, Philippines	May 1997
21 st Annual McCall Conference (invited); “Management of Acute Stroke Diagnosis and Treatment,” McCall, Idaho	January 1998
Psychiatry Grand Rounds to College of Medicine (invited); “New Treatment for Parkinson’s Disease,”	March 1998
Grand Rounds to College of Nursing (invited); “Pathophysiological Changes Associated with Ischemic Stroke,” Tucson, AZ	October 2000
Grand Rounds at Texas Tech Internal Medicine (invited); “Progress in Stroke Prevention and Treatment.” Amarillo, TX	November 2000
Grand Rounds at Oregon Health Sciences University (invited): “Medicine in Space – Long Term Effect.” Portland, OR	June 2001
Grand Rounds to College of Medicine (invited); “William M. Feinberg Memorial Conference,” Tucson, AZ	October 2001
Grand Rounds at University of Alabama (invited); “Vascular Disease and Stroke – New Therapies.”	October 2001
American Academy of Neurology 54 th Annual Meeting (invited); “Practical and Controversial Issues in Stroke Care.” Denver, CO	April 2002
Grand Rounds talk (invited); Neurology Consultants of Tuscaloosa – “Antiplatelet Therapies for Patients Who Suffer a TIA or Stroke.” In Tuscaloosa, AL	May 2002
Grand Rounds talk (invited); “Stroke” for University of California San Diego	May 2002
Everest Regional Summit on Atherothrombosis (Invited); “Focus on Antithrombotic Therapy for Stroke Prevention,” Web conference.	June 2002
Grand Rounds talk (invited); “Antiaggregate Therapy in Stroke.” At University of Minnesota.	June 2002
University of Tennessee 3 rd Annual Stroke Treatment in the New Millenium; “ A Prevention: Choices in Antiplatelet Therapy,” Chattanooga, TN	November 2002

University of Tennessee (invited) November Stroke Treatment Conference; “Secondary Stroke Prevention; Choices in Antiplatelet Therapy,” Chattanooga, TN November 2003

Grand Rounds to College of Medicine (invited); “William M. Feinberg Memorial Conference,” Tucson, AZ February 2004

14th Annual Southwest Conference on Medicine (invited); “Strokes Update – Revascularization.” Westward Look Resort, Tucson, AZ March 2004

Grand Rounds to College of Medicine (invited); “Neurology in the 21st Century – A Tribute to William A Sibley,” Tucson, AZ October 2004

5th Annual Chattanooga Stroke Treatment Conference (keynote speaker invited); “Antiplatelet Therapy for Stroke Treatment.” Chattanooga, TN November 2004

Grand Rounds to College of Medicine (invited); “William M. Feinberg Memorial Conference,” Tucson, AZ May 2006

Medical Grand Rounds at THMEP (invited): “Stroke Prevention Update” Tucson Medical Center, Tucson, AZ September 2006

Grand Rounds for Neurology (invited); “Antiplatelets and Stroke” at University of Texas, San Antonio, TX December 2006

Stroke Conference at Indiana University (invited) “Secondary Stroke Prevention”, Indianapolis, IN March 2007

Surgery Grand Rounds (invited): “Stroke Prevention Update,” Tucson, AZ October 2007

International Stroke Conference 2009 (invited); “Making sense of the role, promise and applicability of stroke biomarkers.” San Diego, CA February 2009

International Stroke Conference 2009 (invited); “New insights in stroke/TIA prevention: Current and emerging data with antithrombotic therapy.” San Diego, CA February 2009

18th Annual Southwestern Conference on Medicine (invited): “Stroke: Updates on Diagnosis/Therapy/Concepts of Neuroplasticity,” Tucson, AZ May 2009

BROADCASTS:

American Stroke Association (invited); “2003 Secondary Stroke Prevention,” Dallas TX November 2003

Research & Review in Neuro News Podcast (invited) “Stroke Prevention”, Tucson AZ April 2007

CURRENT RESEARCH FUNDING: SPONSORED GRANTS FUNDED

FEDERAL

Benavente, Oscar (PI)

03/01/01 - 01/31/09

Secondary prevention of small subcortical strokes – SPS3

The goal of this project is to determine whether combination antiplatelet therapy of ASA plus clopidogrel is superior to ASA for reducing stroke recurrence, cognitive decline, major vascular events and progression of white matter disease, and also to determine whether intensive blood pressure lowering is superior to usual hypertension management for reducing recurrent etc.

Role: PI Neurologist, University of Arizona site

Boehringer-Ingelheim Pharmaceuticals

5/20/04 to 5/19/08

Prevention Regimen for Effectively Avoiding Second Strokes – ProFess

The goal of this project is to determine whether Aggrenox is better than Plavix in preventing stroke. This project will also determine if Micardis can help to prevent a second stroke when given in combination with either extended-release dipyridamole plus ASA, or clopidogrel.

Role: Principal Investigator Neurologist University of Arizona site

Kernan, Walter (PI)

9/15/04 to 6/30/08

Insulin Resistance Intervention After Stroke. (IRIS)

The goal of this project is to test a new approach to preventing stroke or heart attack in patients who have had a stroke. The approach involves taking medication called pioglitazone to reduce insulin resistance.

Role: Co-Investigator University of Arizona Site

Coull, Bruce M. (PI)

4/1/06 to 4/1/2010

Albumin in Acute Stroke – ALIAS Trial

The purpose of this study is to evaluate the effectiveness of high-dose, intravenous human serum albumin in patients who have suffered a stroke. Human serum albumin, a natural protein, is currently in clinical use for a variety of indications. In animal lab studies, it has been shown to reduce the size of the infarction in the brain and improve neurological function after a stroke and to also decrease or eliminate the brain swelling that may occur; these effects may reduce or prevent the brain damage resulting from a stroke in humans.

INDUSTRY

Principal Investigator Neurologist (10%), (University of Arizona site): Boehringer-Ingelheim Pharmaceuticals, “Prevention Regimen for Effectively Avoiding Second Strokes – ProFess”

From 5/20/04 to 5/19/08

The goal of this project is to determine whether Aggrenox is better than Plavix in preventing stroke. This project will also determine if Micardis can help to prevent a second stroke when given in combination with either extended-release dipyridamole plus ASA, or clopidogrel.

PENDING RESEARCH

Principal Investigator (5%) (University of Arizona): “Genetics of Subcortical Cerebral Vasculopathy” – In comparison to normal cerebral blood vessels, gene expression is altered in the small cerebral

blood vessels that underlie leukoaraiosis.

Co-Investigator (5%) (Principal Investigator – Leslie Ritter, Ph.D.) “Inflammatory & Thrombotic Cell Interactions After Stroke”

PREVIOUS GRANTS/AWARDS:

Principle Investigator (University of Arizona site): 07/01/01 - /6/30/04
Treatment of hyperglycemia in ischemic stroke – THIS trial
The goals of this project are to establish the feasibility and tolerability of tight control of hyperglycemia with intravenous insulin during acute ischemic stroke.

Co-Principle Investigator (University of Arizona site): 8/01/03 – 7/31/05
Warfarin vs Aspirin in reduced cardio ejection fraction (WARCEF)
The goal of this project is to determine if warfarin or aspirin is superior for prevention of all-cause mortality or stroke in patients with ejection fraction $\leq 30\%$ when balanced against the risk of intracerebral hemorrhage.

Co-Investigator (University of Arizona site): 9/10/02 to 6/30/06
Treatment of Hyperglycemia in Ischemic Stroke – THIS Trial
The goals of this project are to establish the feasibility and tolerability of tight control of hyperglycemia with intravenous insulin during acute ischemic stroke.

Principle Investigator (University of Arizona site): 8/1/03 to 7/31/05
Vitamin intervention for stroke prevention (VISP)
Blood samples collected during the VISP study will be analyzed for thrombomodulin and fibrinogen

Principle Investigator (University of Arizona site): 9/18/96 to 1/1/00
Glaxo Wellcome – “Ascending dose study to examine the safety and pharmacokinetics of GV150526A.

Principle Investigator (University of Arizona site): 7/1/98 to 6/30/99
Interneuron – Quintiles CVA, Inc. “The effects of 2000mg Citicoline on clinical outcome and the evolution of lesion volume in human stroke.”

Principle Investigator (University of Arizona site): 10/31/96 to 12/31/99
Genentech – “A phase IV study of activase (alteplase, recombinant) in acute ischemic stroke.”

Principle Investigator (University of Arizona site): 3/1/98 to 8/30/99
Columbia University – “Glycine antagonist in neuroprotection.” Gain III.

Principle Investigator (University of Arizona site): Genentech 3/26/92 to 12/31/98
“Thrombolytic therapy in acute ischemic stroke.”

Principle Investigator (University of Arizona site): Emory University 10/1/96 to 9/30/98
“Factor V mutation, APC resistance and Cryptogenic stroke in the young.”

Principle Investigator (University of Arizona site): HFHSC – “Pharmacology and dose ranging study of

HU23F2G in patients with ischemic stroke.”

9/1/97 to 3/1/98

Principle Investigator (University of Arizona site): Nascet – “Research on stenosis, stroke, TIA, and aspirin.” Completed.

Henry Ford Health Sciences Center, “Pharmacology and dose ranging study of HU232F2G in patients with ischemic stroke, 9/1/97 to 3/1/98, Total funding \$72,000.

Principal Investigator: NINDS NS17493-08 "Mechanism of Injury and Repair in Ischemic Stroke". January 1, 1991 to December 31, 1995. Total funding \$3,900,000.

Sponsor for Wayne M. Clark: Clinical Investigator Development Award, " Role of Leukocyte Adhesion in CNS Ischemic Injury", NINDS, 1/91-12/95. Total funding: \$417,933.

Sponsor for Wayne M. Clark: Research Fellowship Award, National Stroke Association/Allied Signal Corp., 1/91-12/92. Total funding: \$60,000.

Principal Investigator: VAMC Merit Review Grant. "Recurrent Stroke: Role of spontaneous echo contrast and blood viscosity". Oct 1, 1992 - Oct 1, 1995. Total Direct Funding \$212,000.

Principal Investigator and Medical Director: VAMC Environmental Hazards Center Award. "Environment, Veterans' Health, and Gulf War Syndrome" with Peter S. Spencer PhD Co-PI and Scientific Director. Aug 1, 1994 to July, 1995. Total award \$2,6000,000.

Principal Investigator for Oregon Center: "Citicoline in Acute Ischemic Stroke", Aug 1994-1995. Interneuron Pharm. Current Funding \$45,000.

Principal Investigator for Oregon VAMC Center: "Clopidogrel vs Aspirin in recurrent stroke." Feb 1992 - Dec 1995. Sterling-Winthrope Co. Current Funding \$340,000 (approx).

Principal Investigator: C6S-19755 "Double-Blind, Placebo-Controlled Pilot Study Evaluating Safety and Tolerability of Two Intravenous Bolus Doses of C6S-19755 in Treatment of Patients with Acute Ischemic Stroke". December 1, 1990 to November 30, 1994. CIBA-GEIGY Corp. Total funding \$182,000 (est).

Co-Principal Investigator at Oregon Center: NS 24224, "Stroke Prevention in Atrial Fibrillation (SPAF I, II & III), 1987 - 1994. Total funding \$85,000. Principal Investigator for Multi-Center Study: Robert G. Hart, M.D., University of Texas, San Antonio.

Principal Investigator for Oregon Center: RO1 NS24456, "North American Symptomatic Carotid Endarterectomy Trial", March 1988 - 1994. Total funding \$431,000. Principal Investigators for Multi-Center Study: HJM Barnett, M.D. and S. J. Peerless, M.D., The John P. Roberts Research Institute, London, Ontario, Canada, N6A 5K8.

Principal Investigator: NS 17493, "Mechanisms of Injury and Repair in Ischemic Stroke", Principal Investigator and Medical Director: VAMC Environmental Hazards Center Award. "Environment, Veterans' Health, and Gulf War Syndrome" with Peter S. Spencer PhD Co-PI and Scientific Director. Aug 1, 1994 to Oct 1, 2000. total award \$2,6000,000.

Principal Investigator: C6S-19755 "Double-Blind, Placebo-Controlled Pilot Study Evaluating Safety and Tolerability of Two Intravenous Bolus Doses of C6S-19755 in Treatment of Patients with Acute

Ischemic Stroke". December 1, 1990 to November 30, 1994. CIBA-GEIGY Corp. Total funding \$182,000 (est).

Co-Principal Investigator at Oregon Center: NS 24224, "Stroke Prevention in Atrial Fibrillation (SPAF I, II & III), 1987 - 1994. Total funding \$85,000. Principal Investigator for Multi-Center Study: Robert G. Hart, M.D., University of Texas, San Antonio.

Principal Investigator for Oregon Center: RO1 NS24456, "North American Symptomatic Carotid Endarterectomy Trial", March 1988 - 1994. Total funding \$431,000. Principal Investigators for Multi-Center Study: HJM Barnett, M.D. and S. J. Peerless, M.D., The John P. Roberts Research Institute, London, Ontario, Canada, N6A 5K8.

Principal Investigator for Oregon Center: "Citicoline in Acute Ischemic Stroke", Aug 1994-1995. Interneuron Pharm. Current Funding \$45,000.

Principal Investigator for Oregon VAMC Center: "Clopidogrel vs Aspirin in recurrent stroke." Feb 1992 - Dec 1995. Sterling-Winthrope Co. Current Funding \$340,000 (approx)., University of Iowa. Total funding \$85,000.

Principal Investigator: "Use of Lovastatin and Omega-3 fatty acids in management of risk for cerebrovascular disease". April 1990 - May 1992. Merck Pharmaceuticals. Total funding \$42,000.

Principal Investigator: Ancrod (Arvin) in Ischemic Stroke: Study No A-20-IV, Knoll Pharmaceuticals. August 1989 - June 1991. Total funding est. \$97,000.

Principal Investigator: MRF 8541 "Hemorheology in Stroke", June 1, 1986 to June 30, 1987, Total funding \$12,000.

Principle Investigator: NIH - Small Instrument Grant: Darkroom Equipment, \$6,872, 1987-88

Principal Investigator: NS 17493, "Stroke Clinical Research Center", August 1, 1983 - July 31, 1985, Total funding \$229,997.

Principal Investigator: MRF 804 Coull 281 "Investigation of Possible Neurotransmitters in the Rat Visual System", March 1, 1980 to February 28, 1981, Total funding \$12,000.

Principal Investigator: Evaluation of TA-3090 in Patients with Previous Strokes. Marion Merrill Dow. Total Funding \$162,832.

Biomedical Research Support Grant - NIH (BRSG): Liquid Scintillation Counter Purchase, \$12,000, 1979, Co-Investigator.

Biomedical Research Support Grant: Laboratory computer purchase, \$4,000, 1981, Co-Investigator.

Biomedical Research Support Grant: Effect of Ischemia on Neurons in Primary Visual Cortex, \$2,250, 1986, Co-Investigator.